TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Feb 21, 2023 14:02 JST
Source:
Eisai
Dissolution of Bracco-Eisai Joint Venture
TOKYO, Feb 21, 2023 - (JCN Newswire) - Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. As a result, Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Co., Ltd. as of April 1, 2023.
Bracco and Eisai established Bracco-Eisai in 1990 with the aim of establishing a contrast agent business in Japan. The companies launched the non-ionic contrast agent Iomeron and the macrocyclic non-ionic contrast agent ProHance for MRI in 1994, and have worked together in a friendly partnership for more than 30 years. After comprehensive consideration, the companies decided to dissolve the joint venture in order to respond quickly and flexibly to the changing environment surrounding the healthcare industry and achieve sustainable contributions to patients through these products.
Regarding Iomeron and ProHance, products that Eisai and Bracco-Eisai have co-promoted thus far, Eisai and Bracco-Japan will continue to co-promote these products between April 1, 2023 and March 31, 2024, with Bracco-Japan as the domestic manufacturer and Eisai as the distributor. Bracco Japan will exclusively commercialize the products from April 1, 2024.
"The Asia-Pacific region plays a leading role in diagnostic imaging and is expected to grow faster than other global markets," said Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging S.p.A. "Bracco has had a considerable presence in Japan for many years and will continue to strengthen its relationships with customers in order to better understand and meet the needs of customers in Japan. We will continue to provide better diagnostic imaging technology and services."
"We are deeply grateful to Bracco, with whom we have worked together for more than 30 years since Bracco-Eisai's founding to contribute to patients in the field of diagnostic imaging." said Haruo Naito, Chief Executive Officer at Eisai Co., Ltd. "Based on our human health care concept, Eisai will continue to play a role in providing information on both Iomeron and ProHance until the end of March 2024, and will take all possible measures to ensure a smooth transfer of operations, so that Bracco Japan can maintain its contribution to patients."
Media Inquiries:
Bracco Imaging S.p.A.
Bracco Imaging Media Relations
TEL: +39-340-9016191
Bracco Eisai Co.,Ltd
Public Relations
TEL: +81-(0)3-5319-3381
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
More Press release >>
Latest Press Release
Hitachi Employee Receives the "Chop Wood Carry Water Award" from the Global OSS Organization CNCF for Leading the Establishment of Official Community in Japan
Nov 14, 2025 21:06 JST
The University of Osaka D3 Center and NEC Demonstrate Wide-Area Distributed Campus AI Processing Platform
Nov 14, 2025 00:41 JST
Toyota to Invest Up to $10 Billion Additional in Its U.S. Operations Over the Next Five Years
Nov 14, 2025 00:08 JST
MHI Thermal Systems Launches Magnetic Bearing Centrifugal Chiller "ETI-N" Series for Japanese Market
Nov 13, 2025 23:34 JST
MHI Completes Joint Demonstration with Kirin Group for Automation of Warehouse Operations, and Truck Loading and Unloading
Nov 13, 2025 23:00 JST
JCB launches second round of Shopping Mall Shuttle Free Ride Campaign in Guam
Nov 13, 2025 11:00 JST
NTT, NTT DOCOMO: Establishment of the AI Technology "Large Action Model (LAM)" to Accelerate 1-to-1 Marketing
Nov 12, 2025 19:00 JST
Mitsubishi Power Receives Second H-25 Gas Turbine Order for Chang Chun Petrochemical's Miaoli Factory in Taiwan
Nov 12, 2025 18:43 JST
All-New Delica Mini and eK Space Win RJC Car of the Year Award for 2026
Nov 12, 2025 18:00 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Announces TK-SR Rhodium Material for Use in Probe Pins
Nov 12, 2025 11:00 JST
Hitachi and Tobu Railway launched a co-creation initiative to deliver HMAX on Japanese railways
Nov 11, 2025 17:35 JST
World Premiere of the New Hilux in Asia
Nov 10, 2025 20:29 JST
MHI Signs EPC Contract for Large-Scale Ammonia and Urea Fertilizer Production Complex for the State Concern Turkmenhimiya
Nov 10, 2025 19:51 JST
Mitsubishi Heavy Industries Announces Order Intake, Revenue, and Profit Growth in Strong 1H FY2025, Raises Full-Year Order Intake and Revenue Guidance
Nov 10, 2025 19:17 JST
MHI Reaches a Basic Agreement with J-POWER on the Transfer of its Domestic Onshore Wind Power Business
Nov 10, 2025 18:40 JST
JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data
Nov 10, 2025 18:01 JST
NEC Wheelchair Singles Masters 2025 to begin
Nov 10, 2025 17:32 JST
Indicio Secures Investment from NEC X, Accelerating A New Era of User-Controlled Digital Identity
Nov 10, 2025 17:00 JST
The 18th JCB World Conference Held in Incheon, Republic of Korea
Nov 07, 2025 18:00 JST
Olympus Unveils Corporate Strategy
Nov 07, 2025 15:30 JST
More Latest Release >>